Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival.
Sooman L, Lennartsson J, Gullbo J, Bergqvist M, Tsakonas G, Johansson F, Edqvist PH, Pontén F, Jaiswal A, Navani S, Alafuzoff I, Popova S, Blomquist E, Ekman S.
Sooman L, et al. Among authors: blomquist e.
Med Oncol. 2013;30(3):638. doi: 10.1007/s12032-013-0638-0. Epub 2013 Jun 20.
Med Oncol. 2013.
PMID: 23783486